ADRX
ADARx Pharmaceuticals, Inc.
Price Chart
Latest Quote
$18.13
+0.32 (+1.80%)
Current Price
| Previous Close | $17.81 |
| Open | $17.99 |
| Day High | $18.80 |
| Day Low | $17.71 |
| Volume | 293,616 |
Stock Information
| Shares Outstanding | 110.74M |
| Total Debt | $6.90M |
| Cash Equivalents | $427.25M |
| Revenue | $6.13M |
| Net Income | $-87.87M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.01B |
| EPS (TTM) | $-1.18 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.87B |
| Sales | $6.13M |
| Income | $-87.87M |
| Book/sh | $-22.16 |
| Cash/sh | $3.86 |
| Employees | 100 |
Financial Ratios
| Quick Ratio | 12.56 |
| Current Ratio | 12.98 |
| Debt/Eq | 6.47 |
Returns & Margins
| Operating Margin | -4006.84% |
Ownership
| Insider Ownership | 41.78% |
| Institutional Ownership | 45.44% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -11.98 |
| P/S | 327.68 |
| P/B | -0.82 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $34.25 |
Technical Indicators
| SMA20 | $18.03 |
| RSI | 63.61 |
| ATR | 1.2179 |
| Shares Float | 49.42M |
| Short Ratio | 0.62 |
| Rel Volume | 0.57 |
Performance History
| Week | +2.55% |
| Month | -9.76% |
| YTD | -6.30% |
| 10 Years | -6.30% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $18.13 | 293,600 |
| 2026-10-26 | $17.81 | 99,600 |
| 2026-10-23 | $17.63 | 177,600 |
| 2026-10-22 | $17.68 | 181,500 |
| 2026-10-21 | $17.13 | 441,500 |
| 2026-10-20 | $17.68 | 1,074,900 |
| 2026-10-19 | $17.63 | 262,000 |
| 2026-10-16 | $17.65 | 247,100 |
| 2026-10-15 | $17.70 | 283,400 |
| 2026-10-14 | $17.83 | 285,500 |
| 2026-10-13 | $17.70 | 221,000 |
| 2026-10-12 | $17.97 | 350,800 |
| 2026-10-09 | $17.78 | 688,500 |
| 2026-10-08 | $17.68 | 420,200 |
| 2026-10-07 | $17.33 | 705,600 |
| 2026-10-06 | $18.58 | 1,034,900 |
| 2026-10-05 | $19.05 | 913,900 |
| 2026-10-02 | $18.25 | 937,000 |
| 2026-10-01 | $19.54 | 962,200 |
| 2026-09-30 | $19.94 | 788,800 |
| 2026-09-29 | $20.64 | 1,299,400 |
| 2026-09-28 | $20.09 | 1,205,200 |
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-Ã precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on ADRX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $3,449,000 | $0 |
| Operating Revenue | $3,449,000 | $0 |
| Expenses | ||
| Total Expenses | $91,814,000 | $58,233,000 |
| Other Income Expense | $1,636,000 | $478,000 |
| Other Non Operating Income Expenses | $1,636,000 | $478,000 |
| Net Non Operating Interest Income Expense | $13,641,000 | $11,395,000 |
| Operating Expense | $91,814,000 | $58,233,000 |
| General And Administrative Expense | $20,302,000 | $14,876,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-73,088,000 | $-46,360,000 |
| Net Interest Income | $13,641,000 | $11,395,000 |
| Interest Income | $13,641,000 | $11,395,000 |
| Normalized Income | $-73,088,000 | $-46,360,000 |
| Net Income From Continuing And Discontinued Operation | $-73,088,000 | $-46,360,000 |
| Total Operating Income As Reported | $-88,365,000 | $-58,233,000 |
| Net Income Common Stockholders | $-73,088,000 | $-46,360,000 |
| Net Income | $-73,088,000 | $-46,360,000 |
| Net Income Including Noncontrolling Interests | $-73,088,000 | $-46,360,000 |
| Net Income Continuous Operations | $-73,088,000 | $-46,360,000 |
| Pretax Income | $-73,088,000 | $-46,360,000 |
| Interest Income Non Operating | $13,641,000 | $11,395,000 |
| Operating Income | $-88,365,000 | $-58,233,000 |
| Per Share | ||
| Diluted EPS | $-0.97 | $-0.62 |
| Basic EPS | $-0.97 | $-0.62 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-86,038,000 | $-56,731,000 |
| Reconciled Depreciation | $2,327,000 | $1,502,000 |
| EBITDA (Bullshit earnings) | $-86,038,000 | $-56,731,000 |
| EBIT | $-88,365,000 | $-58,233,000 |
| Diluted Average Shares | $75,346,354 | $75,310,297 |
| Basic Average Shares | $75,346,354 | $75,310,297 |
| Diluted NI Availto Com Stockholders | $-73,088,000 | $-46,360,000 |
| Research And Development | $71,512,000 | $43,357,000 |
| Selling General And Administration | $20,302,000 | $14,876,000 |
| Other Gand A | $20,302,000 | $14,876,000 |
Fetched: 2026-10-27
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-202,255,000 | $-137,145,000 |
| Total Assets | $507,655,000 | $233,454,000 |
| Total Non Current Assets | $14,280,000 | $7,787,000 |
| Other Non Current Assets | $2,210,000 | $660,000 |
| Current Assets | $493,375,000 | $225,667,000 |
| Other Current Assets | $13,379,000 | $6,189,000 |
| Cash Cash Equivalents And Short Term Investments | $479,996,000 | $219,478,000 |
| Cash And Cash Equivalents | $66,517,000 | $14,034,000 |
| Debt | ||
| Total Debt | $7,741,000 | $4,329,000 |
| Long Term Debt And Capital Lease Obligation | $6,028,000 | $3,535,000 |
| Current Debt And Capital Lease Obligation | $1,713,000 | $794,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $709,910,000 | $370,599,000 |
| Total Non Current Liabilities Net Minority Interest | $679,425,000 | $361,662,000 |
| Other Non Current Liabilities | $781,000 | $505,000 |
| Non Current Deferred Liabilities | $314,994,000 | $0 |
| Current Liabilities | $30,485,000 | $8,937,000 |
| Current Deferred Liabilities | $16,557,000 | $0 |
| Payables And Accrued Expenses | $9,338,000 | $4,843,000 |
| Payables | $5,844,000 | $1,346,000 |
| Accounts Payable | $5,844,000 | $1,346,000 |
| Equity | ||
| Common Stock Equity | $-202,255,000 | $-137,145,000 |
| Total Equity Gross Minority Interest | $-202,255,000 | $-137,145,000 |
| Stockholders Equity | $-202,255,000 | $-137,145,000 |
| Gains Losses Not Affecting Retained Earnings | $1,955,000 | $335,000 |
| Other Equity Adjustments | $1,955,000 | $335,000 |
| Retained Earnings | $-220,699,000 | $-147,611,000 |
| Preferred Securities Outside Stock Equity | $357,622,000 | $357,622,000 |
| Other | ||
| Ordinary Shares Number | $102,200,905 | $102,200,905 |
| Share Issued | $102,200,905 | $102,200,905 |
| Tangible Book Value | $-202,255,000 | $-137,145,000 |
| Invested Capital | $-202,255,000 | $-137,145,000 |
| Working Capital | $462,890,000 | $216,730,000 |
| Capital Lease Obligations | $7,741,000 | $4,329,000 |
| Total Capitalization | $-202,255,000 | $-137,145,000 |
| Additional Paid In Capital | $16,489,000 | $10,131,000 |
| Capital Stock | $0 | $0 |
| Common Stock | $0 | $0 |
| Non Current Deferred Revenue | $314,994,000 | $0 |
| Long Term Capital Lease Obligation | $6,028,000 | $3,535,000 |
| Current Deferred Revenue | $16,557,000 | $0 |
| Current Capital Lease Obligation | $1,713,000 | $794,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,877,000 | $3,300,000 |
| Current Accrued Expenses | $3,494,000 | $3,497,000 |
| Net PPE | $12,070,000 | $7,127,000 |
| Accumulated Depreciation | $-3,539,000 | $-2,539,000 |
| Gross PPE | $15,609,000 | $9,666,000 |
| Leases | $358,000 | $189,000 |
| Construction In Progress | $28,000 | $286,000 |
| Other Properties | $15,093,000 | $9,138,000 |
| Machinery Furniture Equipment | $130,000 | $53,000 |
| Properties | $0 | $0 |
| Other Short Term Investments | $413,479,000 | $205,444,000 |
Fetched: 2026-10-27
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $259,353,000 | $-49,018,000 |
| Operating Activities | ||
| Operating Cash Flow | $262,288,000 | $-48,563,000 |
| Cash Flow From Continuing Operating Activities | $262,288,000 | $-48,563,000 |
| Investing Activities | ||
| Capital Expenditure | $-2,935,000 | $-455,000 |
| Investing Cash Flow | $-209,925,000 | $39,514,000 |
| Cash Flow From Continuing Investing Activities | $-209,925,000 | $39,514,000 |
| Financing Activities | ||
| Financing Cash Flow | $97,000 | $225,000 |
| Cash Flow From Continuing Financing Activities | $97,000 | $225,000 |
| Other | ||
| End Cash Position | $66,517,000 | $14,034,000 |
| Beginning Cash Position | $14,034,000 | $22,852,000 |
| Effect Of Exchange Rate Changes | $23,000 | $6,000 |
| Changes In Cash | $52,460,000 | $-8,824,000 |
| Proceeds From Stock Option Exercised | $97,000 | $225,000 |
| Net Investment Purchase And Sale | $-206,990,000 | $39,969,000 |
| Sale Of Investment | $196,500,000 | $221,000,000 |
| Purchase Of Investment | $-403,490,000 | $-181,031,000 |
| Net PPE Purchase And Sale | $-2,935,000 | $-455,000 |
| Purchase Of PPE | $-2,935,000 | $-455,000 |
| Change In Working Capital | $329,811,000 | $-564,000 |
| Change In Other Working Capital | $331,551,000 | - |
| Change In Other Current Liabilities | $-862,000 | $-705,000 |
| Change In Other Current Assets | $-1,548,000 | $-631,000 |
| Change In Payables And Accrued Expense | $4,358,000 | $1,347,000 |
| Change In Accrued Expense | $-115,000 | $1,570,000 |
| Change In Payable | $4,473,000 | $-223,000 |
| Change In Account Payable | $4,473,000 | $-223,000 |
| Change In Prepaid Assets | $-3,688,000 | $-575,000 |
| Stock Based Compensation | $6,127,000 | $3,948,000 |
| Amortization Of Securities | $-2,889,000 | $-7,089,000 |
| Depreciation Amortization Depletion | $2,327,000 | $1,502,000 |
| Depreciation And Amortization | $2,327,000 | $1,502,000 |
| Depreciation | $2,327,000 | $1,502,000 |
| Net Income From Continuing Operations | $-73,088,000 | $-46,360,000 |
Fetched: 2026-10-27